COVID Protection After Transplant-Immunosuppression Reduction
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This study will enroll individuals who have:
- Completed, at a minimum, a full 2-dose course of either the Moderna messenger RNA (mRNA)
based coronavirus infectious disease 19 (COVID-19) vaccine or the Pfizer-BioNTech mRNA
based COVID-19 vaccine, and
- A negative or indeterminate (<0.8 U/mL) antibody response measured at least 30 days
after the last dose of vaccine.
This group of patients is at high risk for severe COVID-19 disease due to pharmacologic
immunosuppression and a high prevalence of non-transplant risk factors such as obesity and
diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)